- 07 lug.- 14:00

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Business Wire.
  • The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)
  • Numab’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate


Modifica consenso Cookie